Tokai plans for Phase III trial of galeterone in 2015

Tokai Pharmaceuticals — a US-based biotechnology company — went public yesterday and was supposedly able to raise more than enough money to initiate a pivotal, Phase III, randomized clinical trial of its investigational drug galeterone (TOK-001) in treatment of late stage prostate cancer. … READ MORE …

Tokai gets funding to expand Phase II trial of galeterone in CRPC

In April 2012 we had noted that Tokai Pharmaceuticals was planning to initiate a Phase II trial of its investigational drug galeterone (also known as TOK-001) in the treatment of men with castration-resistant prostate cancer (CRPC). The company has now announced that it has the funding to expand enrollment in this Phase II trial. … READ MORE …

Tokai to move TOK-001 (galeterone) into Phase II trials later in year

According to a media release issued on Saturday by Tokai Pharmaceuticals, their investigational agent galeterone (TOK-001) “was well-tolerated with minimal side effects and demonstrated efficacy” in a Phase I clinical trial among men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

TOK-001 enters clinical trials for CRPC

A new, oral drug called TOK-001, made by Tokai Pharmaceuticals, will shortly enter Phase I/II clinical trials for the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …